Alamar Biosciences, Inc.
NASDAQ:ALMRBiotechnology
+$1.11 today
- Market cap
- $2.12B
- Beta
- 0.00
- P/E (TTM)
- -47.5
- EPS (TTM)
- -$0.45
Volume 0.53M
Average 0.38M
ALMR Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Alamar Biosciences, Inc.NASDAQ: ALMR
Other Income / Expenses · Q2 FY2026 · quarter ended Jun 2026
Other income / expenses of $240K in Q2 FY2026
Q2 FY2026 other income / expenses was $240K.
Context
- Other income / expenses amounted to 2.9% of revenue in FY2025.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 2.18M USD
- Year-over-year change
- —
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.18M | — |
Other Income / Expenses vs competitors
How ALMR compares with its peers on the latest reported figures
- ALMR's FY2025 other income / expenses of $2.18M is the 6th highest of the 9 companies compared; the peer median is $5.65M.
- Other income / expenses amounts to 2.9% of revenue for ALMR, versus a peer median of 10.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $35.01M | -78.7% | — | 21.9% | |
| LTM Sep 2026 | $8.85M | -85.1% | -13.5% | 1.9% | |
| LTM Sep 2026 | $7.04M | -61.3% | +128.2% | 1.1% | |
| LTM Mar 2026 | $7.03M | -30.0% | +11.2% | — | |
| LTM Mar 2026 | $4.27M | -57.4% | -0.2% | 28.4% | |
ALMRAlamar Biosciences, Inc. | FY2025 | $2.18M | — | — | 2.9% |
| LTM Mar 2026 | -$7.6M | -178.5% | — | 410.1% | |
| LTM Mar 2026 | -$9.32M | -198.2% | — | 10.8% | |
| LTM Sep 2026 | -$13.45M | -269.3% | — | 1.1% | |
| Peer median (excluding ALMR) | $5.65M | -81.9% | +5.5% | 10.8% | |
Competitors are the stored peer set for ALMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Revenue | 74.21M |
| Cost of Revenue | 32.51M |
| Gross Profit | 41.71M |
| Gross Margin | 56.2% |
| Research & Development | 37.47M |
| Selling, General & Admin | 35.57M |
| Operating Expenses | 73.04M |
| Depreciation & Amortization | 3.86M |
| EBITDA | (24.89M) |
| EBITDA Margin | -33.5% |
| Operating Income | (31.33M) |
| Operating Margin | -42.2% |
| Interest Income | 2.16M |
| Interest Expense | 401K |
| Other Income / Expenses | 2.18M |
| Income Before Tax | (29.15M) |
| Pre-Tax Margin | -39.3% |
| Income Tax Expense | 665K |
| Net Income | (29.82M) |
| Net Margin | -40.2% |
| EPS (Basic) | (0.45) |
| EPS (Diluted) | (0.45) |
| Weighted Avg Shares | 66.52M |
| Weighted Avg Shares (Diluted) | 66.52M |
Alamar Biosciences, Inc.
NASDAQ:ALMR
Intrinsic Alpha fair value
Locked
Current Price
$30.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.